Many cytokine inhibitors, including those targeting IL‐1β, IL‐6, and TNF‐α, have been approved for the treatment of inflammatory diseases, such as bone destruction and rheumatoid arthritis (Rao et al., 2013). This evidence concerns the gene IL6 and rheumatoid arthritis.